{"id":42749,"date":"2026-01-20T11:00:00","date_gmt":"2026-01-20T11:00:00","guid":{"rendered":"http:\/\/www.prnasia.com\/story\/archive\/4866587_AE66587_0"},"modified":"2026-01-20T11:00:00","modified_gmt":"2026-01-20T11:00:00","slug":"4dmedical-secures-us100-million-funding-to-accelerate-u-s-expansion-and-increase-technology-dominance-in-software-based-lung-imaging","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=42749","title":{"rendered":"4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging"},"content":{"rendered":"

Funding will scale hospital deployments for groundbreaking <\/b>CT:VQ\u2122 imaging product, <\/b>strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more<\/b><\/p>\n

LOS ANGELES and MELBOURNE, Australia<\/span>, Jan. 20, 2026<\/span> \/PRNewswire\/ — 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ\u2122” product and significantly boost research and development\u2014bolstering 4D’s technology lead in software-based lung imaging.<\/p>\n

\"Backed<\/a>
Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ\u2122 software.<\/span> <\/div>\n

CT:VQ\u2122 is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.<\/p>\n

“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ\u2122. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”<\/p>\n

What the funding enables for hospitals and health systems<\/b><\/p>\n

4DMedical will use the funding to expand U.S. availability of CT:VQ\u2122 and support health systems with implementation at scale, including:<\/p>\n